222834-30-2

Usage

Uses

Used in Pharmaceutical Industry:
(-)-2(S)-Ethoxy-3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]propionic acid is used as a pharmaceutical compound for its potential therapeutic applications. Its unique structure and functional groups may contribute to its efficacy in treating various medical conditions. Further research is required to explore its full potential and optimize its use in the development of new drugs.

Upstream product

• 325793-74-6 (S)-methyl 2-ethoxy-3-(4-hydroxyphenyl)propanoate 
• 302344-84-9 ethyl 2-(10H-phenoxazin-10-yl)acetate 
• 869093-43-6 (S)-4-(3-(2,5-dimethoxyphenyl)-2-hydroxy-3-oxopropyl)phenyl pivalate 
• 869093-41-4 (S)-4-(2-(benzhydryloxy)-3-(2,5-dimethoxyphenyl)-3-oxopropyl)phenyl pivalate 
• 92199-64-9 2-(10H-phenoxazin-10-yl)-1-ethanol 
• 4397-53-9 p-benzyloxybenzaldehyde 
• 325793-65-5 (2S)-2-Ethoxy-3-(4-hydroxyphenyl)propanoic acid 
• 325793-71-3 (S)-2-ethoxy-3-(4-hydroxyphenyl)propanoic acid isopropyl ester 
• 493031-10-0 Ethyl-(2R/2S)-2-ethoxy 3-{4-[2-(10H-phenoxazin-10-yl)ethoxy]phenyl}propanoate 
• 222834-11-9 (+/-)-methyl 3-(4-(2-(10H-phenoxazin-10-yl)ethoxy)phenyl)-2-ethoxypropanoate 
• 222835-03-2 3-(4-benzyloxy-phenyl)-2-ethoxy-acrylic acid ethyl ester 
• 197299-16-4 ethyl 2-ethoxy-3-(4-hydroxy-phenyl)-propionate 
• 222835-09-8 2-(10H-Phenoxazin-10-yl)ethyl methanesulfonate 
• 59012-91-8 2,2-dimethyl-propionic acid 4-hydroxymethyl-phenyl ester 

Downstream Products

• 222834-28-8 [(2S),N(1S)]-3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxy-N-(2-hydroxy-1-phenylethyl)propanamide 
• 264268-43-1 (+/-) 3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid, potassium salt 
• 222834-22-2 (+/-) 3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid, sodium salt 

Relevant academic research and scientific papers

Asymmetric phase-transfer catalyzed glycolate alkylation, investigation of the scope, and application to the synthesis of (-)-ragaglitazar

Asymmetric glycolate alkylation using a protected acetophenone surrogate under solid-liquid phase-transfer conditions is a new approach to the synthesis of 2-hydroxy esters and acids. Diphenylmethyloxy-2,5-dimethoxyacetophenone 1 with a trifluorobenzyl ci

ABC EXPRESSION PROMOTERS

The ABCA1 mRNA expression-promoting agent, LXRα mRNA expression-promoting agent, ABCG1 mRNA expression-promoting agent, cholesterol efflux-promoting agent, cholesteryl ester accumulation-inhibiting agent, ACAT-1 mRNA expression-inhibiting agent and CEH mRNA expression-promoting agent of the present invention are excellent in the ability to control cholesterol distribution in the body and have low toxicity.

Synthesis and biological and structural characterization of the dual-acting peroxisome proliferator-activated receptor α/γ agonist ragaglitazar

A new and improved synthesis of the peroxisome proliferator-activated receptor (PPAR) agonist ragaglitazar applicable for large-scale preparation has been developed. The convergent synthetic procedure was based on a novel enzymatic kinetic resolution step

Process for the preparation of new antidiabetic agents

The present invention relates to an improved process for the preparation of novel antidiabetic compounds having formula (1) where R1represents hydrogen or lower alkyl group and X represents hydrogen or halogen atom.

Crystalline R-guanidines, arginine or (L)-arginine (2S)-2-ethoxy-3-{4-[2-(10H-phenoxazin-10-yl)ethoxy]phenyl}propanoate

The present invention relates to crystalline R-guanidines of (2S)-2-Ethoxy-3-{4-[2-(10H-phenoxazin-10-yl)ethoxy]phenyl}propanoate, its preparations and its use as therapeutic agents. More specifically the present invention relates to crystalline Arginine (2S)-2-Ethoxy-3-{4-[2-(10H-phenoxazin-10-yl)ethoxy]phenyl}propanoate, preferably (L)-Arginine (2S)-2-Ethoxy-3-{4-[2-(10H-phenoxazin-10-yl)ethoxy]phenyl}propanoate, its preparation and its use as therapeutic agent.

Tricyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them

A compound of formula (1) it derivatives, its analogs, its tautomeric forms, its stereoisomers, its polymorphs, its pharmaceutically acceptable salts, or its pharmaceutically acceptable solvates, processes for its preparation and methods of use thereof.

(-)3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid [(-)DRF 2725]: A dual PPAR agonist with potent antihyperglycemic and lipid modulating activity

(-)DRF 2725 (6) is a phenoxazine analogue of phenyl propanoic acid. Compound 6 showed interesting dual activation of PPARα and PPARγ. In insulin resistant db/db mice, 6 showed better reduction of plasma glucose and triglyceride levels as compared to rosig

Tricyclic compounds and their use in medicine process for their preparation and pharmaceutical compositions containing them

Novel beta -aryl- alpha -oxysubstituted alkylcarboxylic acids of the formula (I) and compositions containing them. The compounds have hypolipidemic, antihyperglycemic uses.